Inhibition of Cyclin‐Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy

Therapeutic options for patients with advanced‐stage hepatocellular carcinoma (HCC) are very limited. The only approved first‐line treatment is the multi‐tyrosine kinase inhibitor sorafenib, which shows low response rates and severe side effects. In particular, the compensatory activation of growth...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardelt, Maximilian A., Fröhlich, Thomas, Martini, Emanuele, Müller, Martin, Kanitz, Veronika, Atzberger, Carina, Cantonati, Petra, Meßner, Martina, Posselt, Laura, Lehr, Thorsten, Wojtyniak, Jan‐Georg, Ulrich, Melanie, Arnold, Georg J., König, Lars, Parazzoli, Dario, Zahler, Stefan, Rothenfußer, Simon, Mayr, Doris, Gerbes, Alexander, Scita, Giorgio, Vollmar, Angelika M., Pachmayr, Johanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590289/
https://www.ncbi.nlm.nih.gov/pubmed/30033593
http://dx.doi.org/10.1002/hep.30190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590289/
https://www.ncbi.nlm.nih.gov/pubmed/30033593
http://dx.doi.org/10.1002/hep.30190

Ejemplares similares